BECTON DICKINSON & CO BDX
NYSE · XNYS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
6/9
Piotroski F — financial health
2.29
Altman Z″ — distress risk · grey
71.3%
Dividend payout · stretched
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $21.8B | $1.7B | — | $2.7B | $25.4B |
| 2024 | $20.2B | $1.7B | — | $3.1B | $25.9B |
| 2023 | $19.4B | $1.5B | — | $2.1B | $25.8B |
| 2022 | $18.9B | $1.8B | — | $1.5B | $25.3B |
| 2021 | $19.1B | $2.1B | — | $2.9B | $23.7B |
| 2020 | $16.1B | $874.0M | $7.6B | $2.2B | $23.8B |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 2.29 (grey)
- Working capital / assets 0.017
- Retained earnings / assets 0.3
- EBIT / assets 0.047
- Equity / liabilities 0.848
Source: SEC EDGAR filings · CIK 0000010795 · as of 2025-09-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.